The H3K9 methyltransferase SETDB1 has been reported to play a tumor suppressor role by limiting the expression of genes targeted by MLL1 fusion proteins (72), contraindicating SETDB1 inhibition in the treatment of MLLr leukemias. This evidence concerns the gene KMT2A and leukemia.